Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19.
作者信息
Walther Thomas, Kuebler Wolfgang M
机构信息
Department of Pharmacology and Therapeutics, School of Medicine and School of Pharmacy, University College Cork, Cork, Ireland.
Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, Greifswald, Germany.
出版信息
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1023-L1024. doi: 10.1152/ajplung.00118.2020.
Abstract
摘要
相似文献
1
Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19.勿轻率评判：肾素-血管紧张素系统的多方面作用及其在新冠病毒肺炎中的治疗潜力
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1023-L1024. doi: 10.1152/ajplung.00118.2020.
2
Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19".致编辑信件的回复：“勿轻率评判：肾素 - 血管紧张素系统的多面作用及其在 COVID - 19 中的治疗潜力”
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1029-L1030. doi: 10.1152/ajplung.00133.2020.
3
The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?肾素-血管紧张素系统与新型冠状病毒2019感染：血管紧张素转换酶2受体的作用？
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926911. doi: 10.1177/1470320320926911.
4
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.对近期有关血管紧张素转换酶2（ACE2）和肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关性的评论的回应
Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.
5
COVID-19, Renin-Angiotensin System, and Hematopoiesis.新型冠状病毒肺炎、肾素-血管紧张素系统与造血作用
Turk J Haematol. 2020 Aug 28;37(3):207-208. doi: 10.4274/tjh.galenos.2020.2020.0174. Epub 2020 May 12.
6
What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?在新冠病毒肺炎（COVID-19）中，关于肾素-血管紧张素系统抑制剂的应用，需要何种证据来指导实践？
Hypertension. 2020 Sep;76(3):665-669. doi: 10.1161/HYPERTENSIONAHA.120.15712. Epub 2020 Aug 12.
7
Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎患者的预后：一项病例系列研究。
Hypertension. 2020 Aug;76(2):e10-e12. doi: 10.1161/HYPERTENSIONAHA.120.15312. Epub 2020 May 8.
8
Inquiring Into Benefits of Independent Activation of Nonclassical Renin-angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality.探究非经典肾素-血管紧张素系统的独立激活在COVID-19临床预后及降低死亡率方面的益处。
Clin Infect Dis. 2020 Jul 28;71(15):894-895. doi: 10.1093/cid/ciaa402.
9
Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?肾素-血管紧张素-醛固酮系统抑制剂对2019冠状病毒病死亡率的影响：血管紧张素转换酶2的下一步是什么？
Clin Infect Dis. 2020 Nov 19;71(16):2129-2131. doi: 10.1093/cid/ciaa627.
10
Comment on "ACE inhibitors and COVID-19: We don't know yet".关于《血管紧张素转换酶抑制剂与2019冠状病毒病：我们尚不清楚》的评论
J Card Surg. 2020 Jun;35(6):1387. doi: 10.1111/jocs.14647.
引用本文的文献
1
Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.沙坦类药物在 SARS-CoV-2 刺突 RBD-ACE2 结合中的计算和酶学研究：四唑的作用及作为抗高血压和 COVID-19 治疗药物的前景。
Int J Mol Sci. 2023 May 8;24(9):8454. doi: 10.3390/ijms24098454.
2
Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.乙酰氨基阿维菌素可减轻血管紧张素 II 收缩作用并与严重急性呼吸综合征冠状病毒 2 的刺突蛋白相互作用。
Biomedicines. 2022 Jul 18;10(7):1731. doi: 10.3390/biomedicines10071731.
3
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.从血管紧张素 II 到环肽和血管紧张素受体阻滞剂 (ARB)：ARB 在 COVID-19 治疗中的观点。
Molecules. 2021 Jan 25;26(3):618. doi: 10.3390/molecules26030618.
4
Pneumonia in the face of COVID-19.面对新冠疫情时的肺炎
Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L863-L866. doi: 10.1152/ajplung.00447.2020. Epub 2020 Sep 30.
5
Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19".致编辑信件的回复：“勿轻率评判：肾素 - 血管紧张素系统的多面作用及其在 COVID - 19 中的治疗潜力”
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1029-L1030. doi: 10.1152/ajplung.00133.2020.
6
Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection.征文启事：新型冠状病毒肺炎及严重急性呼吸综合征冠状病毒2感染的病理生理学
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1016-L1019. doi: 10.1152/ajplung.00136.2020. Epub 2020 Apr 8.
本文引用的文献
1
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
2
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.中国武汉 2019 年冠状病毒病死亡和康复病例的临床特征：回顾性研究。
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267. doi: 10.1097/CM9.0000000000000824.
3
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
4
Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies.新型冠状病毒肺炎感染与死亡率：生理学家视角下的临床特征与可行干预策略解析
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1020-L1022. doi: 10.1152/ajplung.00097.2020. Epub 2020 Mar 24.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Therapeutic time window for angiotensin-(1-7) in acute lung injury.血管紧张素-（1-7）在急性肺损伤中的治疗时间窗
Br J Pharmacol. 2016 May;173(10):1618-28. doi: 10.1111/bph.13462. Epub 2016 Mar 21.
9
Angiotensin-(1-7) protects from experimental acute lung injury.血管紧张素-(1-7)可预防实验性急性肺损伤。
Crit Care Med. 2013 Nov;41(11):e334-43. doi: 10.1097/CCM.0b013e31828a6688.
10
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.血管紧张素转换酶2（ACE2）在严重急性呼吸综合征冠状病毒诱导的肺损伤中的关键作用。
Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.
Zotero 插件